December 20, 2024

Workplace Discrimination in Ophthalmology

“Your husband also works, so you’re the second income.’”

Conexiant

December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 13, 2024

Obstructive Sleep Apnea Affects nAMD

The potential overnight reduction of the critical oxygen supply could present a retinal health risk.

Conexiant

December 13, 2024

Faricimab Shows Better Anatomic Outcomes Compared to Aflibercept for nAMD

New data from TENAYA and LUCERNE supports “the vascular stabilizing effects of Ang-2 inhibition beyond anti-VEGF-A alone.”

Conexiant

December 13, 2024

Detailed Connections between Geographic Atrophy Lesions and Vision Loss

Study explores discord between BCVA and GA lesion size.

Conexiant

August 01, 2023

E-insights Into the Latest in Patient Care and Practice Management

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Optometric Management

September 18, 2024

Assessing the Impact of iRORA Lesions on Retina Sensitivity and Function

A new case study explores the impact of incomplete retinal pigment epithelium and outer retinal atrophy lesions on retinal sensitivity in intermediate age-related macular degeneration, shedding light on potential surrogate markers for retinal dysfunction. (Source: BMJ Open Ophthalmology)

Conexiant

September 30, 2024

Can L-DOPA Protect Against nAMD?

Patients consistently treated with L-DOPA also had lower progression rates from intermediate AMD to nAMD compared to non-treated groups.

Conexiant

October 01, 2023

Preventing Conversion to Advanced AMD

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Optometric Management